We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 38,838 | 08:00:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/4/2020 22:33 | Dave - I agree completely with you! | finster007 | |
03/4/2020 22:06 | I expect a bounce next week now the tax year end profit take is over! | dave444 | |
03/4/2020 22:04 | If Blackrock continue to reduce Link’s holding we could see further drop next week while we continue to pick up new holders. Depends how much of Woodford’s holding is left, I guess. | wetdream | |
03/4/2020 21:51 | It looks like the city boys have been loading for their clients for what's coming or that is what the gent on the lse board who worked as an institutional sales/trader in the 90s thinks. | likya123 | |
03/4/2020 21:43 | Likya. What is that to do with here is it a cross stock ramp. | dealer55 | |
03/4/2020 21:32 | Definitely | the patient investor | |
03/4/2020 21:04 | It does look like we have had to absorb a big volume seller which looks like the RNS amounts and another 3 million or so if in fact he has sold out fully. Those late trades are pretty big so someone buying. Expected 70p this week at close shame, maybe next week will be better. I wonder what next news will be update on recent USA appearance or manufacturing agreements? Update on patient numbers? I think we will get some sort of news next week. | crookie3634 | |
03/4/2020 20:53 | From JCEP lse board... Brokers are so dodgy on AIM. Late and large delayed buy orders on the 2nd ! Hunch tells me they are legging into their big clients. I get it...you have to pay the ferryman. This tells me one is being lined up here. I was an institutional sales/trader in the 90s...the patterns are increasingly clear. I’m long the stock and remain bullish over next 6 weeks. | likya123 | |
03/4/2020 20:37 | I am fuming to be honest .. they talked about medical trial just to deflect away from the mega balls up on testing . One jorno asked why Germany and south Korea are doing great work i.e. have less deaths ? the replies were utter trash to be honest . Test and test again should be the mantra else the virus is going to spread and spread resulting in more deaths dont they understand .. | pal44 | |
03/4/2020 20:34 | Patient Investor, thought u was maxed out elsewhere, or did u sell some of ur golden shares to join the gang here | yet another final | |
03/4/2020 20:28 | Haha likya, you have a habit of repeating my posts - keep it up, it’s always good to see it more than once ;) | makendon | |
03/4/2020 20:12 | Nobby what should I drink to forget the losses? | adman50 | |
03/4/2020 19:46 | tx Lykia, great find and just published today I agree, the verb chosen is very promising i made it clickable | the patient investor | |
03/4/2020 19:42 | "The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed" "Confirm" is an interesting word choice and almost as if they know it works but just getting confirmation. I like this choice of word, it fills me with yet more confidence about what's about to happen here. Urgent public health studies! A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection Study type: Interventional Summary: The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed. Chief Investigator: Professor Tom Wilkinson University Hospital Southampton NHS Foundation Trust Sponsor: Synairgen Research Limited Funder: Synairgen Research Limited IRAS Number: 281317 CPMS ID: 45382 | likya123 | |
03/4/2020 19:22 | Andrew Pierce has it and is off air. | bmnsa | |
03/4/2020 19:21 | Only those with the lergy can apply(covid19) | bmnsa | |
03/4/2020 18:38 | 3fiona I did listen to it too, impressive accurate summary! thx | the patient investor | |
03/4/2020 18:35 | From BBC Prof Van Tam: Search for treatments ongoingProfessor Jonathan Van Tam says to find the most effective treatments you need to find out "the right dosage to use, the right patient to give it to and the right time to give it".The deputy chief medical officer says it is "complicated stuff and the only way to unpick signals and get it right is clinical trials".He confirms there are three trials already running, and the recruitment rate has been "astonishing".The trials are focusing on existing drugs that may be used for something else, but they are going to move on to looking at new medicines in development.Prof van Tam cannot give a date for when this will happen, saying it is going to be a "few months", "but it will all depend how quickly patients are recruited into the trials".He adds: "The faster we go... the clearer and more emphatic signals we will get about what works and who it works for." | 3fiona | |
03/4/2020 17:59 | Just found this updated or released today :) Titled: Urgent public health studies! A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection Study type: Interventional Summary: The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed. Chief Investigator: Professor Tom Wilkinson University Hospital Southampton NHS Foundation Trust Sponsor: Synairgen Research Limited Funder: Synairgen Research Limited IRAS Number: 281317 CPMS ID: 45382 | makendon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions